Login
Super Investors Pfizer Inc
P

Pfizer Inc

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$164M
Positions
17
Quarter ended
September 30, 2026
Filed
November 12, 2026

Reported portfolio value by quarter (8 quarters reported)

$2.59B $164M
Q4 24 Q2 25 Q4 25 Q2 26 Q3 26

$2.59B in Q4 2024 → $164M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
AT Allogene Therapeutics Inc 22.1% Unchanged 22,032,040 $36.4M
Arvinas Inc 16.0% Unchanged 3,457,815 $26.2M
Celcuity Inc 14.3% Unchanged 295,652 $23.5M
Agomab Therapeutics Nv 13.8% Added 2768% 2,151,213 $22.6M
PO Pyxis Oncology Inc 12.2% Unchanged 7,032,770 $20.1M
Wave Life Sciences Inc 4.3% New 1,875,000 $7.09M
Biohaven Ltd 4.0% Unchanged 505,645 $6.57M
Caribou Biosciences Inc 3.5% Unchanged 4,690,431 $5.82M
Oric Pharmaceuticals Inc 3.0% Unchanged 372,904 $4.91M
Cardiff Oncology Inc 1.8% Unchanged 2,411,575 $2.99M
Spero Therapeutics Inc 1.8% Unchanged 2,362,348 $2.91M
Zentalis Pharmaceuticals Inc 1.6% Unchanged 953,834 $2.58M
Zura Bio Ltd 1.3% Unchanged 538,841 $2.18M
Nextcure Inc 0.1% Added 0.0% 44,357 $225K
Bolt Biotherapeutics Inc 0.1% Unchanged 31,305 $112K
Ginkgo Bioworks Holdings Inc 0.0% Unchanged 2,928 $31.2K
SH Senseonics Hldgs Inc 0.0% New 2,171 $21.7K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 12, 2026

Company Action Shares changed Value of change % of portfolio
Agomab Therapeutics Nv Added +2,076,213 +$21.8M 13.8%
Wave Life Sciences Ltd Exited −1,875,000 −$10.9M —
Wave Life Sciences Inc New +1,875,000 +$7.09M 4.3%
SH Senseonics Hldgs Inc New +2,171 +$21.7K —
SH Senseonics Hldgs Inc Exited −2,171 −$12.4K —
Nextcure Inc Added +10 +$51 0.1%

Q2 2026

quarter ended June 30, 2026 · filed August 13, 2026

Company Action Shares changed Value of change % of portfolio
Oric Pharmaceuticals Inc Trimmed −4,407,497 −$42M 2.1%
Zura Bio Ltd Trimmed −2,300,072 −$12.3M 1.7%
Q32 Bio Inc Exited −101,618 −$737K —
Nextcure Inc Trimmed −109,007 −$179K —

Q1 2026

quarter ended March 31, 2026 · filed May 12, 2026

Company Action Shares changed Value of change % of portfolio
Oric Pharmaceuticals Inc Trimmed −595,943 −$7.19M 24.1%
Celcuity Inc Trimmed −53,754 −$5.7M 13.1%
Q32 Bio Inc Trimmed −176,159 −$1.28M 0.3%
An2 Therapeutics Inc Exited −715,295 −$815K —
Agomab Therapeutics Nv New +75,000 +$814K 0.3%
Zura Bio Ltd Trimmed −131,109 −$777K 7.1%
Nextcure Inc Trimmed −4,292 −$43K 0.6%

Q4 2025

quarter ended December 31, 2025 · filed February 12, 2026

Company Action Shares changed Value of change % of portfolio
Biontech Se Exited −1,658,361 −$164M —
Tourmaline Bio Inc Exited −1,272,214 −$60.8M —
Essa Pharma Inc Exited −1,675,000 −$320K —
SH Senseonics Hldgs Inc Trimmed −41,255 −$228K —

Q3 2025

quarter ended September 30, 2025 · filed November 13, 2025

Company Action Shares changed Value of change % of portfolio
Biontech Se Trimmed −2,000,000 −$197M 37.4%
Nextcure Inc New +157,646 +$924K 0.2%
Nextcure Inc Exited −157,646 −$870K —

Q2 2025

quarter ended June 30, 2025 · filed August 11, 2025

Company Action Shares changed Value of change % of portfolio
Nextcure Inc Trimmed −1,734,117 −$9.57M 0.2%
Bolt Biotherapeutics Inc Exited −626,109 −$250K —
Bolt Biotherapeutics Inc New +31,305 +$181K —

Q1 2025

quarter ended March 31, 2025 · filed May 13, 2025

Company Action Shares changed Value of change % of portfolio
Haleon PLC Exited −197,228,952 −$1.88B —
Akero Therapeutics Inc Exited −562,626 −$15.7M —
Nextcure Inc Added +433,213 +$208K 0.2%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support